These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17823118)

  • 1. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.
    Criswell TL; Arteaga CL
    J Biol Chem; 2007 Nov; 282(44):32491-500. PubMed ID: 17823118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
    Criswell TL; Dumont N; Barnett JV; Arteaga CL
    Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
    You HJ; How T; Blobe GC
    Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
    Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
    Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
    Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.
    Gatza CE; Elderbroom JL; Oh SY; Starr MD; Nixon AB; Blobe GC
    Neoplasia; 2014 Jun; 16(6):489-500. PubMed ID: 25077702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
    Zhang S; Sun WY; Wu JJ; Gu YJ; Wei W
    Oncol Rep; 2016 Apr; 35(4):2373-81. PubMed ID: 26882862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
    Yan Z; Deng X; Friedman E
    J Biol Chem; 2001 Jan; 276(2):1555-63. PubMed ID: 11029459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.
    Elderbroom JL; Huang JJ; Gatza CE; Chen J; How T; Starr M; Nixon AB; Blobe GC
    Mol Biol Cell; 2014 Aug; 25(16):2320-32. PubMed ID: 24966170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.
    Lambert KE; Huang H; Mythreye K; Blobe GC
    Mol Biol Cell; 2011 May; 22(9):1463-72. PubMed ID: 21411633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
    Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
    Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of TGF-β receptor III localization in polarity and breast cancer progression.
    Meyer AE; Gatza CE; How T; Starr M; Nixon AB; Blobe GC
    Mol Biol Cell; 2014 Aug; 25(15):2291-304. PubMed ID: 24870032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor.
    Pal A; Huang W; Toy KA; Kleer CG
    Neoplasia; 2012 Nov; 14(11):1067-74. PubMed ID: 23226100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition.
    Huang JJ; Corona AL; Dunn BP; Cai EM; Prakken JN; Blobe GC
    Oncogene; 2019 May; 38(18):3402-3414. PubMed ID: 30643193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.
    You HJ; Bruinsma MW; How T; Ostrander JH; Blobe GC
    Carcinogenesis; 2007 Dec; 28(12):2491-500. PubMed ID: 17768179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
    Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
    Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
    Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells.
    Mythreye K; Knelson EH; Gatza CE; Gatza ML; Blobe GC
    Oncogene; 2013 Mar; 32(11):1416-27. PubMed ID: 22562249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-dependent and -independent interactions with the transforming growth factor type II and I receptor subunits reside in the aminoterminal portion of the ectodomain of the type III subunit.
    Taniguchi A; Matsuzaki K; Nakano K; Kan M; McKeehan WL
    In Vitro Cell Dev Biol Anim; 1998 Mar; 34(3):232-8. PubMed ID: 9557941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.